cedirogant

Cedirogant is an orally bioavailable small molecule inverse agonist of retinoic acid-related orphan receptor gamma thymus (RORγt), a nuclear receptor that regulates the differentiation and function of Th17 cells and the production of interleukin 17A (IL‑17A). By inhibiting RORγt activity, cedirogant blocks the IL‑17/IL‑23 signaling pathway implicated in the pathogenesis of psoriasis. It was developed primarily for moderate to severe chronic plaque psoriasis but has also been investigated for liver disorders. Cedirogant was originally discovered by Inventiva Pharma and further developed by AbbVie. Clinical studies demonstrated pharmacokinetic properties suitable for once-daily oral dosing and showed numerical improvements in disease severity scores in psoriasis patients; however, development has been discontinued for both plaque psoriasis and liver disorders[1][3][5][6][7].

Other names

(1-(2,4-dichloro-3-((7-chloro-5-(trifluoromethyl)-1h-indol-1-yl)methyl)benzoyl)piperidin-4-yl)acetic acid4-piperidineacetic acid, 1-(2,4-dichloro-3-((7-chloro-5-(trifluoromethyl)-1h-indol‑1‑yl)methyl)benzoyl)-